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A B S T R A C T
Objective: To explore the effect of granisetron, a 5-HT3
antagonist, on fatigue and functional impairment in
patients with chronic fatigue syndrome (CFS).
Methods: Five female patients were eligible to receive oral
granisetron for one month (1 mg a day for the first two
weeks and 2 mg a day for the second two weeks). The
patients had to be between 18 and 65 years of age and
suffering from CFS according to the CDC criteria. The
effect was assessed by pre- and post-testing, using validated
instruments designed to assess the different dimensions
of CFS. Treatment response was also evaluated by visual
analogue scales (VAS) for fatigue. Analysis was based on
intention to treat.
Results: Treatment with granisetron resulted in significant
improvement in fatigue severity and functional impairment.
Activity level showed no significant increase.
Conclusion: The promising results of this study have
encouraged us to perform a placebo-controlled, double-blind
study to evaluate the efficacy of 5-HT3 receptor antagonists
in the treatment of CFS.
I N T R O D U C T I O N
Chronic fatigue syndrome (CFS) is a medically unexplained
syndrome, characterised by severe disabling fatigue for a
period of at least six months, which has led to considerable
impairment in daily functioning.1 Various accompanying
symptoms may be present, such as headache, joint and
muscle pain, sore throat, and impaired memory and
concentration. Of the many therapeutic interventions that
have been undertaken so far, only cognitive behaviour
therapy (CBT) and graded exercise therapy (GET) have
met with succes.2,3
There is accumulating data in the literature supporting
an important role for serotonin (5-hydroxytryptamine) in
the neurobiology of CFS. Neuropharmacological studies
point to an upregulated serotonin system.4-7
In a randomised controlled trial by our own research
group, the selective serotonin reuptake inhibitor (SSRI)
fluoxetine proved to be ineffective in CDC-diagnosed CFS
subjects for the treatment of fatigue and depression,8 which
is also in line with upregulation of the serotonin system.
Positive reports of the use of serotonin inhibitors in the
treatment of patients with fatigue (due to chronic hepatitis9
and to fibromyalgia10,11) support an effect. Based on these
findings, we hypothesise that a serotonin antagonist
could be effective in CFS. Therefore, we undertook this
pilot study.
M A T E R I A L S  A N D  M E T H O D S
Patients
Five female CDC-diagnosed patients with a high fatigue
level and a substantial impairment in daily life, reflected
by the Checklist Individual Strength (CIS)12,13 and the
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Sickness Impact Profile-8 (SIP-8),14,15 were treated with
granisetron. The cut-off point of the CIS fatigue severity
subscale was set at 40 and the weighted total score of the
SIP-8 was set at 800.
In a CBT multicentre, randomised controlled trial by our
research group, the CBT treatment protocol did not seem
to be suitable for a group of CFS patients with low activity
patterns.2 Therefore, we selected patients with a low activity
pattern. Patients whose average daily physical activity
scores stayed below the reference score in at least nine of
the twelve assessment days could be included.16 The activity
level was assessed prior to the treatment period with an
actometer. We chose only female subjects, because in
CFS the ratio male/female is approximately 1:417 and
combined with low activity as a disease characteristic, we
created a homogeneous group.
Additional criteria were patients aged between 18 and 65
years, and no previous or current engagement in CFS
research. Pregnant or lactating women and patients who
were taking psychotropic medications were excluded. We
received ethical clearance to perform a pilot study and
obtained written informed consent from all patients.
Design and procedures
There were four evaluation moments (E1-E4): E1 at baseline,
E2+E3, in the middle and at the end of the treatment
period and E4 at follow-up, two weeks after the treatment
period. The treatment period was divided in two periods
of two weeks. During the first period, the patients received
an oral dose of granisetron of 1 mg a day. After two weeks
the effect, compliance and side effects were evaluated. If
the evaluation showed no significant improvement, the
dose was increased to 2 mg a day.
Analysis was based on intention to treat. A linear model
for repeated measures was used to analyse the effect of
granisetron on the outcome measures CIS fatigue severity,
CIS activity and SIP-8.
The four evaluation moments were analysed as well as
the three evaluation moments during the medication
period. The visual analogue scales (VAS) actual fatigue
scores were analysed by the Wilcoxon signed-rank test.
A S S E S S M E N T S
Fatigue severity
The Checklist Individual Strength (CIS) is a reliable and
validated self-report questionnaire. We used the subscale
fatigue severity of the CIS (CIS fatigue severity).12,13 The
score on this eight-item scale ranges from 8 (no fatigue)
to 56 (maximally fatigued).
CIS fatigue severity analysis during the medication
period (E1-E3) calculated a significant decline in time
(p=0.046). The significant drop during the medication period
(E1-E3) means that patients reported significantly lower
fatigue levels after treatment with granisetron. Analysis
over four measurements is significant in time as well
(p=0.026). Follow-up (E4) showed an increase in fatigue
severity after discontinuation of granisetron (figure 1).
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Figure 1
Effect of granisetron in five patients on the outcome
variable fatigue severity (CIS fatigue severity)
Table 1
Effect of granisetron in five patients on the outcome variable
VAS actual fatigue severity (p=0.042)
TREATMENT VAS MEAN SD SEM RANGE MM
E1 – actual 76.4 13.7 6.1 59-95
E2 – actual 65.2 21.4 9.6 34-93
E3 – actual 54.4 28.1 12.6 22-92
Visual analogue scales (VAS) (100 mm) are used to determine
the actual fatigue severity. VAS ratings were used to evaluate
the one-month treatment period. VAS assessments took
place during the medication period (E1, E2 and E3).
The VAS actual fatigue showed a significant drop of 29%
in the mean fatigue scores (p=0.042) during the treatment
period (table 1).
Functional impairment
The sickness impact profile (SIP-8) measures the influence
of symptoms on daily functioning, using the following
eight subscales to rate both physical and psychological
disability: home management, mobility, alertness behaviour,
sleep/rest, ambulation, social interactions, work and
recreation, and pastimes.14,15
SIP-8 analysis during the medication period (E1-E3)
showed a significant decline in time (p=0.008). Patients
reported significantly less functional impairment during
the one-month medication period. Analysis over four
measurements is significant in time as well (p=0.005).
Follow-up (E4) showed an increase in functional impairment
after discontinuation of granisetron. Within two weeks the
mean SIP-8 score returned to the baseline level (figure 2).
Before treatment the mean actometer score was 44.6 (SD
22.2). During the last two weeks of the treatment period
the mean actometer score was 46.2 (SD 20.3).
Granisetron did not significantly change the mean
actometer score (p=0.16).
The subscale activity of the CIS was used (CIS activity).
The score on this three-item scale ranges from 3 (no activity)
to 21 (maximally activity level).12,13
Analysis of the CIS subscale activity showed no significant
improvement during the medication period (p=0.16).
Analysis over four measurements is not significant in
time either (p=0.191).
R E S U L T S
The five women had a mean age of 34 years (range 23-44
years). Three of the five patients had a pervasively passive
actometer pattern. Two patients had activity level scores
lower than the mean CFS score for 9 out of the 12 days.
All patients finished their study.
In the first two weeks the oral dose of 1 mg granisetron was
well tolerated, but none of the patients showed significant
improvement. In the second period all patients received
2 mg granisetron a day.
Four out of five patients reported marked improvement.
One patient did not report any improvement on the
outcome variables fatigue severity, activity level and
functional impairment. Another patient complained of
constipation as a side effect of granisetron during the last
few days of the treatment.
D I S C U S S I O N
In this pilot study we evaluated the effect of granisetron,
a serotonin receptor antagonist, in chronic fatigue syndrome
patients with low activity patterns. We found a substantial
decrease in fatigue and functional impairment in four out
of five patients as assessed by CIS fatigue severity, SIP-8
and visual analogue scale. That these changes in scores
are clinically relevant can be deduced from our observations
that these patients and their partners reported a remarkable
improvement in fatigue and functional impairment at the
end of the treatment period.
That granisetron, a serotonin antagonist, could have a
favourable effect in CFS is not totally unexpected. First
of all, there are reports in the literature pointing to a
postsynaptic hyper-responsiveness in CFS.4,5 Also the
challenge test with buspirone, a 5-HT agonist and
D-fenfluramine, a serotonin reuptake inhibitor, met with
exaggerated prolactine responses in CFS patients, consistent
with a postsynaptic serotonergic hyper-responsiveness in
CFS.6,7
The, et al. Granisetron and chronic fatigue syndrome patients.
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Figure 2
Effect of granisetron in five patients on the outcome
variable functional impairment (SIP-8)
Activity level
The actometer is a small motion-sensing device that can
register and quantify human physical activity.18 Three
different activity patterns can be distinguished for
patients with CFS: pervasively passive, fluctuating active
and pervasively active. In an earlier study identifying
physical activity patterns in CFS patients, we observed that
healthy controls do not fall in the category of pervasively
passive. Patients wore the actometer day and night for a
two-week period. After the two-week period the average
scores over 12 days were computed.16
Second, there are reports in the literature pointing to a
favourable effect of serotonin antagonist in fatigued
patients. Jones reported a positive effect on fatigue in a
35-year-old woman with profound fatigue associated with
chronic hepatitis-C when treated with a 5-HT3 receptor
antagonist.9 Positive results in fibromyalgia studies10,11
also support a favourable effect of serotonin antagonists
in the treatment of fatigue.
A remarkable finding is that within two weeks after dis-
continuation of granisetron, follow-up showed a marked
increased mean fatigue level score and an increased
functional impairment score. Within a few days
granisetron is eliminated from the system (T1/2 elimination
is 9-12 hours). The increase in symptoms within a short
period after discontinuation of the medication supports
the hypothesis that the intervention with granisetron is
responsible for the reported improvement.
In this open study, a placebo effect cannot be excluded.
However, in previous placebo-controlled studies8,19 we
have not encountered remarkable changes in fatigue
severity and functional impairment in the placebo group.
The actometer activity level showed no significant improve-
ment. A possible explanation is that a reduced level of
fatigue will not immediately lead to an increased physical
walking activity level, which is measured by the actometer.
It is possible that CFS patients have quite structured daily
routines. A reduced level of fatigue will probably not
immediately lead to a change in the daily routines. We
treated patients with low activity patterns. In addition
there may be deconditioning of the patients, which is not
reversible in the short term of one month. It might take
more than four weeks to change the rather static activity
patterns, despite a decreased level of fatigue. Perhaps a
longer treatment protocol and a longer registration period
could lead to (significantly) improved actometer activity
levels. However, we do not know whether wearing off
effects occur with prolonged treatment.
It is striking that the outcome measures showed an
improvement of CFS-related symptoms after two weeks
(figures 1 and 2). It is not clear whether the reported
improvement after two weeks can be explained by a dose-
dependent effect. A possible explanation is that time is a
key factor in the reported improvement. It is possible that
granisetron induced a postsynaptic receptor modification
in time or decreased the sensitivity of the postsynaptic
receptors.
Data in the literature point in the direction that CFS and
depression are opposing disease entities with contrasting
neuroendocrine responses and 5-HT functioning.20-22 The
‘serotonin hypothesis’ is the most widely accepted neural
basis for depression. Drugs that preferentially increase
serotonin activity by decreasing its reuptake (selective
serotonin reuptake inhibitor, or SSRI) are effective in the
treatment of depression23-25 and not in the treatment of
CFS, even when the patients are depressed.8
It is worth noting that there is a therapeutic delay of two
weeks in the treatment of depression with a SSRI. It is
conceivable that a similar delay occurs with 5-HT receptor
antagonism as applied in the presented study.
It is remarkable that one patient did not respond. This 23-
year-old woman with a CFS history of three years was no
different from the other patients with regard to her history,
CDC criteria, CIS fatigue severity score and SIP-8 score.
Whether such nonresponsiveness has a serotonergic
neuroendocrine basis has to be investigated in longer
studies combined with serotonergic challenge tests and
with serotonin receptor-status imaging studies. It is known
that granisetron concentrations in blood may vary between
subjects. A lower granisetron concentration might have
caused the nonresponse in this individual. In this pilot
study we did not measure blood granisetron concentrations.
An interesting question is also whether further dose
escalation would enhance the effect.
Our favourable results in this pilot study warrant a study
with a randomised placebo-controlled, double-blind design.
At the present time we are conducting such a randomised
clinical trial with a longer treatment protocol and longer
registration periods. In the future an interesting treatment
concept might be a combination of a 5-HT3 receptor
antagonist with CBT or GET.
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